CL2019000575A1 - Amylin analogs. - Google Patents

Amylin analogs.

Info

Publication number
CL2019000575A1
CL2019000575A1 CL2019000575A CL2019000575A CL2019000575A1 CL 2019000575 A1 CL2019000575 A1 CL 2019000575A1 CL 2019000575 A CL2019000575 A CL 2019000575A CL 2019000575 A CL2019000575 A CL 2019000575A CL 2019000575 A1 CL2019000575 A1 CL 2019000575A1
Authority
CL
Chile
Prior art keywords
analogs
amylin analogs
amiline
affections
diabetes
Prior art date
Application number
CL2019000575A
Other languages
Spanish (es)
Inventor
Dieter Wolfgang Hamprecht
Lise Giehm
Jesper Mosolff Mathiesen
Henrik Kofoed Munch
Jesper Skodborg VILLADSEN
Alexander Heim-Reither
Giacomo Fossati
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of CL2019000575A1 publication Critical patent/CL2019000575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANÁLOGOS DE AMILINA Y SU USO PARA TRATAR O PREVENIR VARIAS ENFERMEDADES, AFECCIONES O TRASTORNOS, QUE INCLUYEN OBESIDAD, INGESTA EXCESIVA DE ALIMENTOS Y ENFERMEDADES METABÓLICAS ASOCIADAS TAL COMO LA DIABETES. LOS ANÁLOGOS PUEDEN TENER UNA BUENA ESTABILIDAD FÍSICA Y QUÍMICA, UNA BUENA SOLUBILIDAD Y UNA DURACIÓN DE ACCIÓN PROLONGADA Y SON MUY ADECUADOS PARA USAR EN FORMA DE FORMULACIÓN LÍQUIDA.THE PRESENT INVENTION REFERS TO AMILINE ANALOGS AND ITS USE TO TREAT OR PREVENT VARIOUS DISEASES, AFFECTIONS OR DISORDERS, INCLUDING OBESITY, EXCESSIVE FOOD INGESTION AND ASSOCIATED METABOLIC DISEASES SUCH AS DIABETES. THE ANALOGS MAY HAVE GOOD PHYSICAL AND CHEMICAL STABILITY, GOOD SOLUBILITY AND LONG TERM OF ACTION AND ARE VERY SUITABLE FOR USE IN LIQUID FORMULATION FORM.

CL2019000575A 2016-09-09 2019-03-07 Amylin analogs. CL2019000575A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09

Publications (1)

Publication Number Publication Date
CL2019000575A1 true CL2019000575A1 (en) 2019-05-10

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000575A CL2019000575A1 (en) 2016-09-09 2019-03-07 Amylin analogs.

Country Status (26)

Country Link
US (4) US10071140B2 (en)
EP (2) EP4074729A1 (en)
JP (1) JP7064103B2 (en)
KR (1) KR102498393B1 (en)
CN (1) CN109863168B (en)
AR (1) AR109514A1 (en)
AU (1) AU2017322277B2 (en)
BR (1) BR112019004534A2 (en)
CA (1) CA3035958A1 (en)
CL (1) CL2019000575A1 (en)
CO (1) CO2019002159A2 (en)
DK (1) DK3510044T3 (en)
EA (1) EA201990360A1 (en)
ES (1) ES2901386T3 (en)
IL (1) IL264864B2 (en)
MA (1) MA46180A (en)
MX (1) MX2019002599A (en)
MY (1) MY197024A (en)
PE (1) PE20190963A1 (en)
PH (1) PH12019500474A1 (en)
SA (1) SA519401239B1 (en)
SG (1) SG11201901423XA (en)
TW (1) TWI784968B (en)
UA (1) UA123369C2 (en)
WO (1) WO2018046719A1 (en)
ZA (1) ZA201901253B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6769984B2 (en) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ Amyrin analogue
TWI784968B (en) * 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 Amylin analogues
JP2023500895A (en) 2019-11-11 2023-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング NPY2 receptor agonist
KR20230045088A (en) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 Soluble NPY2 receptor agonists
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202346323A (en) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 Glp-1 and glucagon dual agonist peptides with improved biological stability
WO2023227133A1 (en) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 Human amylin analog, and derivative and use thereof
AU2023278353A1 (en) 2022-05-30 2024-05-23 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (en) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 Human amylin polypeptide derivative and use thereof
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (en) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
SK88793A3 (en) 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
BRPI9711437B8 (en) 1996-08-30 2021-05-25 Novo Nordisk As glp-1 derivatives
CA2265900C (en) 1996-09-09 2007-07-31 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (en) 1997-06-04 2006-10-03 Frantisek Ziak Fitness-balance board
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (en) 1999-03-17 2001-12-18 Novo Nordisk As Method for acylating an amino group of a peptide or a protein, and, compound
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2006083254A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
JP2007525495A (en) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド Hybrid polypeptides with selectable properties
DE102004051014A1 (en) 2004-10-20 2006-04-27 Rwth Aachen Chemically modified peptide analogues
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CN101400698A (en) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 Amylin derivatives
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
KR101593406B1 (en) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 Glucagon analogues
CN102282166B (en) 2008-12-15 2015-04-01 西兰制药公司 Glucagon analogues
UA104605C2 (en) 2008-12-15 2014-02-25 Зіленд Фарма А/С Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
PL2454282T3 (en) 2009-07-13 2015-08-31 Zealand Pharma As Acylated glucagon analogues
ES2550761T3 (en) 2009-11-25 2015-11-12 Novo Nordisk A/S Method for polypeptide production
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
JP6023048B2 (en) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ Glucagon analog
PL2718316T3 (en) 2011-06-10 2020-06-29 Novo Nordisk A/S Polypeptides
KR20140114845A (en) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 Glucagon analogues
ES2640285T3 (en) 2012-04-19 2017-11-02 Novo Nordisk A/S Human amylin analogs
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
AR097701A1 (en) 2013-09-19 2016-04-13 Zealand Pharma As AMILINE ANALOGS
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2947587C (en) 2014-05-02 2022-10-18 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
ES2887370T3 (en) 2014-09-04 2021-12-22 Novo Nordisk As New amylin and calcitonin receptor agonist
JP6769984B2 (en) * 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ Amyrin analogue
TWI784968B (en) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Also Published As

Publication number Publication date
US10071140B2 (en) 2018-09-11
JP7064103B2 (en) 2022-05-10
KR20190045333A (en) 2019-05-02
ZA201901253B (en) 2022-10-26
CN109863168A (en) 2019-06-07
PH12019500474A1 (en) 2019-08-05
IL264864A (en) 2019-04-30
EP3510044A1 (en) 2019-07-17
IL264864B2 (en) 2023-10-01
AU2017322277A1 (en) 2019-03-28
WO2018046719A1 (en) 2018-03-15
SG11201901423XA (en) 2019-03-28
TW201811818A (en) 2018-04-01
PE20190963A1 (en) 2019-07-08
US11382956B2 (en) 2022-07-12
US20200188485A1 (en) 2020-06-18
JP2019534248A (en) 2019-11-28
AR109514A1 (en) 2018-12-19
US20180071366A1 (en) 2018-03-15
DK3510044T3 (en) 2021-12-13
EA201990360A1 (en) 2019-09-30
EP3510044B1 (en) 2021-11-24
EP4074729A1 (en) 2022-10-19
CA3035958A1 (en) 2018-03-15
US20210346468A1 (en) 2021-11-11
TWI784968B (en) 2022-12-01
US20190134159A1 (en) 2019-05-09
ES2901386T3 (en) 2022-03-22
SA519401239B1 (en) 2023-07-09
MA46180A (en) 2021-03-24
BR112019004534A2 (en) 2019-06-25
KR102498393B1 (en) 2023-02-13
MY197024A (en) 2023-05-22
MX2019002599A (en) 2019-09-18
UA123369C2 (en) 2021-03-24
AU2017322277B2 (en) 2021-11-11
CN109863168B (en) 2023-04-18
IL264864B1 (en) 2023-06-01
CO2019002159A2 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CL2019000575A1 (en) Amylin analogs.
DOP2019000005A (en) 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2
CO2017008870A2 (en) Amylin analogs
GT201600010A (en) PYRROLAMIDE DERIVAODS SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS DRUGS FOR THE TREATMENT OF HEPATITIS B
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
GT201500312A (en) DERIVATIVES OF SULFAMOILPIRROLAMIDA AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
ECSP15014941A (en) ANTI-VIRUS COMPOUNDS FOR RSV
CR20160237A (en) DERIVATIVES OF CARBOXAMIDE AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
DOP2016000109A (en) SOLID FORMS OF ACID {[5- (3-CHLOROPHENYL) -3-HYDROXIPIRIDIN-2-CARBON] AMINO} ACETIC, COMPOSITIONS, AND USES OF THE SAME.
SV2016005257A (en) BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
CR20160518A (en) COMPOUNDS TO TREAT SPINAL MUSCLE ATROPHY
DOP2015000234A (en) ARNi COMPOSITIONS AGAINST COMPONENT C5 OF THE COMPLEMENT AND METHODS FOR USE.
CR20150326A (en) AUTOTAXIN INHIBITORS
UY35980A (en) DERIVATIVES OF SULFAMOILPIRROLAMIDA AS INHIBITORS OF HBV AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
GT201300080A (en) ELABORATION PROCESS FOR PIRIMIDINE DERIVATIVES
UY36224A (en) TRICYCLIC COMPOUNDS OF IMIDAZO-PIRIMIDINONA
UY36875A (en) BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES
CL2018000523A1 (en) Method for the inhibition of lipid absorption and / or the promotion of lipid excretion using d-psychosa
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
CL2017000715A1 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds
BR112016028845A2 (en) compound, pharmaceutical composition and use of a compound
PE20171243A1 (en) ORLISTAT AND ACARBOSA MODIFIED RELEASE COMPOSITION FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
AR103350A1 (en) COMPOSITIONS OF THE NITRIFICATION INHIBITOR AND METHODS OF PREPARATION OF THE SAME
DOP2016000170A (en) COMPOUNDS DERIVED FROM HYDROXIFORMAMIDE AND USES OF THE SAME